Physician profile
Gary Frank Roberts
NPI 1689636599
$3,155.07
in general payments reported to CMS, 2019-2025
29 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.44 · 2020: $151 · 2021: $641 · 2022: $682 · 2023: $594 · 2024: $561 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,258.86 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $297.69 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $257.32 | 2020-2022 | |
| Pfizer INC. | $191.65 | 2021-2023 | |
| Boston Scientific Corporation | $149.83 | 2021-2025 | Watchman Access System, General - Therapies |
| Novo Nordisk INC | $115.80 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $88.19 | 2020-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.43 | 2021-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $72.58 | 2023-2025 | Trintellix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.26 | 2019-2023 | Lifevest |
| Esperion Therapeutics, INC. | $53.41 | 2020-2021 | |
| Kerecis Limited | $51.99 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sanofi-Aventis U.S. LLC | $43.67 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.36 | 2024-2025 | Caplyta |
| Amgen INC. | $39.46 | 2020-2023 | Repatha |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $37.34 | 2019-2023 | Eliquis |
| Dexcom, INC. | $35.87 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $34.94 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $34.22 | 2022-2024 | Dupixent |
| Abbvie INC. | $32.18 | 2025 | |
| Axsome Therapeutics, INC. | $30.46 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.07 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $23.13 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $21.35 | 2025 | Inspire |
| Janssen Biotech, INC. | $18.02 | 2024 | Tremfya |
| Daiichi Sankyo INC. | $17.23 | 2022 | |
| Lilly USA, LLC | $14.85 | 2023 | Mounjaro |
| Glaxosmithkline, LLC. | $11.37 | 2021 | |
| Bardy Diagnostics, INC. | $8.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.